# Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial

> **NCT06332612** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ziauddin University** · enrollment: 30 (actual)

## Conditions studied

- Oral Submucous Fibrosis

## Interventions

- **DRUG:** Metformin Hydrochloride
- **DRUG:** betamethasone dipropionate
- **DRUG:** Pentoxifylline

## Key facts

- **NCT ID:** NCT06332612
- **Lead sponsor:** Ziauddin University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-12
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-01-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06332612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06332612, "Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06332612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*